One-Year Safety and Immunogenicity of Two Formulations of an Adjuvanted Varicella-Zoster Virus (VZV) Subunit Candidate Vaccine in Adult Autologous Hematopoietic Cell Transplant (HCT) Recipients
Year: 2013
Type: article
Abstract: The impaired B and T cell immunity of HCT recipients increases their susceptibility to infectious diseases like herpes zoster (HZ). However, the licensed live-attenuated HZ vaccine is not appropriate for highly immunocompromised individuals. Recombinant subunit vaccines are an alternative to live-attenuated vaccines. VZV glycoprotein E (gE) is an attractive candidate antigen. We report on the safety and immunogenicity of two formulations of a VZV subunit vaccine candidate administered on a 2- or 3-dose schedule to autologous HCT recipients.
Institutions: Abramson Cancer Center, University of Pennsylvania, Duke Medical Center, Dana-Farber Cancer Institute, City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Cleveland Clinic, University of California, San Francisco, University of Minnesota, University of Tennessee Health Science Center, GlaxoSmithKline (Belgium), GlaxoSmithKline (United States)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1969748301